Recent Press Releases

Clarus Therapeutics Reports FDA Advisory Committees Vote on REXTORO(TM) for Low Testosterone in Men

NORTHBROOK, Ill., Sep 18, 2014 -- Clarus Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee and Drug...

Evotec takes legal steps against Andromeda Biotech, Ltd.

Hamburg, Germany - 18 September 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today after careful evaluation that it will take legal steps against Israel-based...

ProQR Announces Pricing of Initial Public Offering

LEIDEN, Netherlands, Sept. 18, 2014 -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per...

Foamix Pharmaceuticals Ltd. Prices Initial Public Offering

REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. ("Foamix Pharmaceuticals", or "Foamix"), a clinical stage specialty...

Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

WHITEHOUSE STATION, N.J.--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for...

Trevena Appoints Adam M. Koppel to the Board of Directors

Trevena Appoints Adam M. Koppel to the Board of Directors September 18, 2014 KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused...

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

HEADLINE2- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202- CV9202 is based on...

Flexion Therapeutics Announces Clinical Hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee

- Company to host conference call tomorrow, September 18, 2014 at 9:00 a.m. ET to discuss the clinical hold BURLINGTON, Mass., Sept. 17, 2014 -- Flexion Therapeutics, Inc. today announced that the...

Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab

WHITEHOUSE STATION, N.J., and MUMBAI, India, Sep 17, 2014 (BUSINESS WIRE) -- Merck & Co., Inc., MRK, -0.40% known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries...

Tokai Pharmaceuticals Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--Sep. 17, 2014-- Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven...

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA,...

Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

-- Data to be Presented at European Society for Medical Oncology Congress in Madrid -- FOSTER CITY, Calif.--Sep. 17, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2...

Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock

Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock - Endo's Proposal Provides Auxilium Shareholders with Substantial Premium, Immediate Cash...

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease Tuesday, 16 September 2014 AstraZeneca and Eli Lilly and Company (Lilly) today...

Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline for a Commercial License to a Novel Muscle Disease Target

Five Prime Therapeutics, Inc. FPRX, +1.82% (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases,...

FDA approves Movantik for opioid-induced constipation

The U.S. Food and Drug Administration today approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. Opioids are a class of drugs that...

University of California proposes creation of new venture fund to invest in UC innovation

The University of California today (Sept. 15) announced the creation of UC Ventures, an independent fund to pursue investments in UC research-fueled enterprises, subject to the approval of the UC...

SIGA Technologies, Inc. Files for Chapter 11 Reorganization

NEW YORK-- SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it...